Citadel Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$265M Sell
4,217,314
-558,304
-12% -$44.7M 0.04% 342
2025
Q4
$455M Sell
4,775,618
-4,130,627
-46% -$405M 0.07% 211
2025
Q3
$870M Buy
8,906,245
+3,501,940
+65% +$363M 0.13% 92
2025
Q2
$580M Sell
5,404,305
-29,250
-0.5% -$2.96M 0.1% 141
2025
Q1
$548M Buy
5,433,555
+502,103
+10% +$50.6M 0.1% 113
2024
Q4
$440M Sell
4,931,452
-4,861,651
-50% -$428M 0.08% 176
2024
Q3
$821M Sell
9,793,103
-2,706,764
-22% -$213M 0.16% 73
2024
Q2
$963M Buy
12,499,867
+3,725,802
+42% +$273M 0.19% 66
2024
Q1
$601M Sell
8,774,065
-207,469
-2% -$13.3M 0.12% 105
2023
Q4
$519M Sell
8,981,534
-12,174,688
-58% -$650M 0.1% 102
2023
Q3
$1.12B Buy
21,156,222
+5,699,874
+37% +$299M 0.24% 38
2023
Q2
$836M Buy
15,456,348
+444,201
+3% +$23.2M 0.17% 51
2023
Q1
$751M Buy
15,012,147
+8,477,836
+130% +$400M 0.17% 57
2022
Q4
$302M Sell
6,534,311
-7,957,191
-55% -$345M 0.07% 198
2022
Q3
$561M Buy
14,491,502
+1,960,393
+16% +$78.6M 0.13% 78
2022
Q2
$467M Sell
12,531,109
-412,621
-3% -$16.8M 0.12% 102
2022
Q1
$573M Buy
12,943,730
+6,424,582
+99% +$278M 0.12% 90
2021
Q4
$277M Buy
6,519,148
+1,785,342
+38% +$75M 0.06% 237
2021
Q3
$205M Sell
4,733,806
-747,071
-14% -$33.1M 0.04% 329
2021
Q2
$234M Buy
5,480,877
+4,646,664
+557% +$195M 0.05% 267
2021
Q1
$32.2M Sell
834,213
-4,295,293
-84% -$163M 0.01% 1445
2020
Q4
$184M Buy
5,129,506
+4,723,216
+1,163% +$170M 0.05% 287
2020
Q3
$15.5M Buy
406,290
+321,066
+377% +$12.4M ﹤0.01% 1800
2020
Q2
$2.99M Sell
85,224
-8,558,697
-99% -$308M ﹤0.01% 3875
2020
Q1
$282M Buy
8,643,921
+2,799,798
+48% +$109M 0.13% 75
2019
Q4
$264M Buy
5,844,123
+194,161
+3% +$8.12M 0.11% 120
2019
Q3
$230M Sell
5,649,962
-297,408
-5% -$12.6M 0.11% 124
2019
Q2
$256M Buy
5,947,370
+5,085,713
+590% +$196M 0.12% 111
2019
Q1
$33.1M Sell
861,657
-3,125,638
-78% -$119M 0.02% 946
2018
Q4
$141M Sell
3,987,295
-4,179,487
-51% -$152M 0.08% 217
2018
Q3
$314M Buy
8,166,782
+1,318,868
+19% +$46.1M 0.14% 88
2018
Q2
$224M Buy
6,847,914
+4,670,982
+215% +$141M 0.11% 130
2018
Q1
$59.5M Buy
2,176,932
+1,567,167
+257% +$42.6M 0.03% 520
2017
Q4
$15.1M Sell
609,765
-1,467,135
-71% -$40.5M 0.01% 1363
2017
Q3
$60.6M Buy
2,076,900
+528,094
+34% +$14.6M 0.05% 450
2017
Q2
$42.9M Buy
1,548,806
+311,867
+25% +$8.28M 0.04% 566
2017
Q1
$30.8M Sell
1,236,939
-6,740,748
-84% -$164M 0.03% 695
2016
Q4
$173M Buy
7,977,687
+3,139,288
+65% +$68.5M 0.17% 80
2016
Q3
$115M Sell
4,838,399
-9,854,699
-67% -$235M 0.12% 133
2016
Q2
$343M Buy
14,693,098
+13,815,151
+1,574% +$299M 0.38% 21
2016
Q1
$16.5M Sell
877,947
-2,667,126
-75% -$46.9M 0.02% 864
2015
Q4
$65.4M Buy
3,545,073
+3,521,705
+15,071% +$63.1M 0.07% 295
2015
Q3
$383K Buy
+23,368
New +$399K ﹤0.01% 5187
2015
Q2
Sell
-1,049,809
Closed -$18.8M 8738
2015
Q1
$18.6M Buy
1,049,809
+223,899
+27% +$3.54M 0.02% 1015
2014
Q4
$10.9M Sell
825,910
-2,974,593
-78% -$38M 0.01% 1339
2014
Q3
$44.9M Buy
3,800,503
+3,604,004
+1,834% +$45.4M 0.05% 472
2014
Q2
$2.51M Sell
196,499
-6,218,338
-97% -$80.9M ﹤0.01% 2512
2014
Q1
$86.7M Buy
6,414,837
+2,606,415
+68% +$34.2M 0.1% 205
2013
Q4
$45.8M Sell
3,808,422
-205,529
-5% -$2.43M 0.06% 394
2013
Q3
$47.1M Sell
4,013,951
-415,765
-9% -$4.5M 0.07% 343
2013
Q2
$41.1M Buy
+4,429,716
New +$37.6M 0.07% 316

Other funds holding BSX

Citadel Advisors's BSX Position: Q1 2026 in Review

Citadel Advisors reduced its Boston Scientific (BSX) stake by 12% in Q1 2026, selling an estimated $44.7M and leaving 4,217,314 shares worth $265M. The position accounts for 0.04% of the portfolio, ranked #342.

Citadel Advisors first reported a position in BSX in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.12B in Q3 2023. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Citadel Advisors held 4,217,314 shares of Boston Scientific worth $265M as of Q1 2026.
  • Citadel Advisors sold 558,304 Boston Scientific shares in Q1 2026, an estimated $44.7M.
  • Boston Scientific made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #342 holding.
  • Citadel Advisors first reported a position in Boston Scientific in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's Boston Scientific position peaked at $1.12B in Q3 2023.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.